TUMOR IMMUNOLOGY

A less personal cancer therapy?

+ See all authors and affiliations

Science  15 Jul 2016:
Vol. 353, Issue 6296, pp. 259-260
DOI: 10.1126/science.353.6296.259-c

Many new cancer therapies are built around the concept of personalized medicine. This includes an emerging class of therapeutic cancer vaccines that induce the immune system to destroy tumor cells expressing patient-specific neoantigens. Such vaccines may not work well for breast cancer, a tumor type that expresses few neoantigens. Conceivably, a therapeutic vaccine could be designed to target tumor-associated antigens that are shared among breast cancer patients, assuming such shared antigens exist. Munson et al. provide evidence that they do. They analyzed T cell receptor (TCR) sequences of tumor-infiltrating lymphocytes in 20 breast cancer patients and found a panel of TCRs shared among patients' tumors and peripheral blood that were not present in peripheral blood of healthy controls.

Proc. Natl. Acad. Sci. U.S.A. 10.1073/pnas.1606994113 (2016).

Navigate This Article